[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Forsyth P, Roldán G, George D, Wallace C, Palmer CA, Morris D, Cairncross G, Matthews MV, Markert J, Gillespie Y, Coffey M, Thompson B, Hamilton M: A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther; 2008 Mar;16(3):627-32
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas.
  • Reovirus is an oncolytic virus with activity in in vivo models of malignant gliomas (MGs).
  • The primary aims were to determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of intratumoral administration of reovirus in patients with recurrent MGs.
  • Response, survival, and time to progression (TTP) were secondary aims.
  • Patients were adults, had Karnofsky Performance score > or = 60, received prior radiotherapy with or without chemotherapy, and had up to the third recurrence of MG.
  • Reovirus was administered intratumorally stereotactically at 1 x 10(7), 1 x 10(8), or 1 x 10(9) tissue culture infectious dose 50 (TCID50) in a volume of 0.9 ml.
  • There were no grade III or IV adverse events (AEs) definitely or probably related to treatment.
  • Median survival was 21 weeks (range, 6-234), and one is alive 54 months after treatment.
  • [MeSH-major] Brain Neoplasms / therapy. Glioma / therapy. Oncolytic Virotherapy / methods. Reoviridae / physiology
  • [MeSH-minor] Adult. Antibodies, Viral / blood. Female. Headache / etiology. Humans. Male. Middle Aged. Muscle Weakness / etiology. Neoplasm Recurrence, Local. Oncolytic Viruses / immunology. Oncolytic Viruses / physiology. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18253152.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral
  •  go-up   go-down


2. Huss WJ, Gray DR, Greenberg NM, Mohler JL, Smith GJ: Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells. Cancer Res; 2005 Aug 01;65(15):6640-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells.
  • Malignantly transformed stem cells represent a potential common nidus for the primary cancer and the recurrent cancer that arises after treatment failure.
  • Putative prostate stem cells and prostate tumor stem cells in benign and malignant human prostate tissue, in primary human prostate xenografts, and in the transgenic adenocarcinoma of the mouse prostate (TRAMP) mouse model of prostate cancer, are defined by expression of breast cancer resistance protein (BCRP), a marker of pluripotent hematopoietic, muscle, and neural stem cells, and by an absence of androgen receptor (AR) protein.
  • In both benign and malignant human prostate tissue, the rare epithelial cells that express BCRP and lack AR protein are localized in the basal cell compartment, survive androgen deprivation, and maintain proliferative potential in the hypoxic, androgen-deprived prostate.
  • Therefore, BCRP expression isolates prostate stem/tumor stem cells from the prostate tissue microenvironment through constitutive efflux of androgen, protecting the putative tumor stem cells from androgen deprivation, hypoxia, or adjuvant chemotherapy, and providing the nidus for recurrent prostate cancer.
  • [MeSH-major] ATP-Binding Cassette Transporters / biosynthesis. Androgens / metabolism. Neoplasm Proteins / biosynthesis. Neoplastic Stem Cells / metabolism. Prostatic Neoplasms / metabolism

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NOVOBIOCIN .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16061644.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA84296; United States / NCI NIH HHS / CA / P01 CA077739; United States / NCI NIH HHS / CA / CA77739; United States / NCI NIH HHS / CA / CA64851; United States / NIEHS NIH HHS / ES / ES07017; United States / NCI NIH HHS / CA / CA64865
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / ATP Binding Cassette Transporter, Sub-Family G, Member 2; 0 / ATP-Binding Cassette Transporters; 0 / Androgens; 0 / Indoles; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Receptors, Androgen; 17EC19951N / Novobiocin; CW5S8OP3VO / tryptoquivaline
  •  go-up   go-down


3. Soares AB, Lins LH, Macedo AP, Pereira-Neto JS, Vargas PA: Fibrosarcoma originating in the mandible. Med Oral Patol Oral Cir Bucal; 2006 May;11(3):E243-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fibrosarcoma is a malignant mesenchymal neoplasm of fibroblasts that rarely affects the oral cavity and can cause local recurrences or metastasis.
  • In this article we describe a case of primary fibrosarcoma in the mandible in a 16-year-old girl.
  • Immunohistochemically the cells only showed immunoreactivity for vimentin and negativity for S-100 protein, CD 68, cytokeratin cocktail, HMB-45, CD34, pan actin HHF 35, desmin, smooth muscle actin and epithelial membrane antigen (EMA).
  • Based on clinical, radiological, histological and immunohistochemical findings the final diagnosis was high-grade intra-osseous fibrosarcoma.
  • The treatment choice was radical surgery with mandibular reconstruction.
  • After one year and nine months of the treatment the patient displayed multiple metastases.
  • Radiation therapy and chemotherapy were used as adjuvant treatment.
  • Unfortunately, the girl died two years after initial diagnosis.

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16648761.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


Advertisement
4. Yokoo H, Kamiya M, Sasaki A, Hirato J, Nakazato Y, Kurachi H: Neurofibromatosis type 1-associated unusual pleomorphic astrocytoma displaying continual malignant progression. Pathol Int; 2001 Jul;51(7):570-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurofibromatosis type 1-associated unusual pleomorphic astrocytoma displaying continual malignant progression.
  • Patients with neurofibromatosis type 1 (NF1) often have gliomas as a complication, most of which are benign pilocytic astrocytomas which have arisen in optic pathways.
  • Partially resected tissue samples showed pleomorphic astrocytoma with abundant xanthoma cells and degenerative structures such as Rosenthal fibers (RF) and eosinophilic granular bodies.
  • Partially resected tumor tissues were composed of monotonous small anaplastic cells with prominent proliferative activity.
  • Postoperative chemotherapy with procarbazine, MCNU and vincristine (PCV) suppressed the residual tumor dramatically, but the regrowing tumor finally became uncontrollable, leading to the patient's death.
  • TP53 mutation was not detected, while p27 immunopositivity was constantly high during malignant progression, suggesting acquisition of proliferative activity to overcome p53 and p27 inhibitory functions.
  • A review of previously published reports failed to reveal any cases of this type.
  • [MeSH-major] Astrocytoma / pathology. Cerebral Ventricle Neoplasms / pathology. Muscle Proteins. Neurofibromatosis 1 / pathology. Thalamus / pathology
  • [MeSH-minor] Adolescent. Antigens, Nuclear. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. DNA Primers / chemistry. DNA, Neoplasm / analysis. Fatal Outcome. Female. Humans. Microfilament Proteins / analysis. Neoplasm Recurrence, Local. Neoplasms, Second Primary / pathology. Nitrosourea Compounds / therapeutic use. Nuclear Proteins / analysis. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational. Procarbazine / therapeutic use. Tumor Suppressor Protein p53 / analysis. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11472572.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / Biomarkers, Tumor; 0 / DNA Primers; 0 / DNA, Neoplasm; 0 / Microfilament Proteins; 0 / Muscle Proteins; 0 / Nitrosourea Compounds; 0 / Nuclear Proteins; 0 / Tagln protein, mouse; 0 / Tumor Suppressor Protein p53; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; RYH2T97J77 / ranimustine
  •  go-up   go-down


5. Maluf FC, Cordon-Cardo C, Verbel DA, Satagopan JM, Boyle MG, Herr H, Bajorin DF: Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatment. Ann Oncol; 2006 Nov;17(11):1677-86
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatment.
  • Both individual and cooperative effects of these gene products may affect the biological behavior of primary bladder cancers and long-term outcome to standard therapy.
  • METHODS: This study retrospectively evaluated the association with survival of mdm-2, p53, and bcl-2 expression in 59 patients with muscle-invasive, node-negative transitional cell carcinoma (TCC) treated with neo-adjuvant chemotherapy followed by locoregional surgery.
  • Each marker was defined as an altered phenotype if >or=20% malignant cells in the primary tumor exhibited staining; normal or minimal expression was defined as <20% cells exhibiting staining.
  • There was no association of molecular markers either alone or in combination with pathologic downstaging after neo-adjuvant chemotherapy.
  • CONCLUSION: The cooperative effects of phenotypes determined by mdm-2, p53, and bcl-2 expression may predict survival in patients with muscle-invasive TCC of the bladder.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16984978.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


6. Orui H, Yamakawa M, Ishikawa A, Tsuchiya T, Ogino T: Malignant intramuscular forearm tumor with overwhelming squamous element. Pathol Int; 2000 Jul;50(7):574-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant intramuscular forearm tumor with overwhelming squamous element.
  • Squamous cell carcinoma (SCC) arising in the skeletal muscle is rare.
  • A malignant spindle cell component was not detected.
  • Neither evidence of another primary site nor skin lesion over the tumor was found and no metastatic lesion was detected in the 5 years since the appearance of the mass.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Muscle Neoplasms / pathology
  • [MeSH-minor] Actins / analysis. Actins / genetics. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Axilla. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Drug Therapy, Combination. Female. Forearm / pathology. Humans. Lymph Node Excision. Lymph Nodes / surgery. Magnetic Resonance Imaging. Mitomycin / administration & dosage. Oncogene Proteins, Fusion / analysis. Oncogene Proteins, Fusion / genetics. Peplomycin / administration & dosage. RNA, Messenger / metabolism. RNA, Neoplasm / analysis. Reverse Transcriptase Polymerase Chain Reaction. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10886743.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] AUSTRALIA
  • [Chemical-registry-number] 0 / Actins; 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / SYT-SSX fusion protein; 50SG953SK6 / Mitomycin; 56H9L80NIZ / Peplomycin; 5J49Q6B70F / Vincristine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


7. Morawietz L, Kuhnen C, Katenkamp D, Le Coutre P, Ladhoff A, Petersen I: Unusual sarcomatoid neoplasm of the lung suggesting a myofibrosarcoma. Virchows Arch; 2005 Dec;447(6):990-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual sarcomatoid neoplasm of the lung suggesting a myofibrosarcoma.
  • Myofibrosarcoma is a rare neoplasm that occurs mainly in the head and neck region and extremities of middle-aged patients.
  • We report the case of a 47-year-old male patient with a malignant mesenchymal pulmonary tumor affecting almost the entire lower left lobe.
  • A major spindle cell component was observed being positive for smooth-muscle actin, calponin, and vimentin, while stainings for desmin, h-caldesmon, alkaline phosphatase (ALK), and extensively studied cytokeratins were negative.
  • Shortly after resection of the primary tumor, the patient showed multiple distant metastases in the contralateral lung, the mediastinal lymph nodes, the left adrenal gland, and the pectoral and deltoid muscle, which responded well to chemotherapy.
  • The case report will discuss the evidence for the final diagnosis of a primary pulmonary myofibrosarcoma and the differential diagnosis of sarcomatoid tumors of the lung.
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry. Male. Middle Aged. Nucleic Acid Hybridization. Pneumonectomy. Sarcoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1973 Jan;31(1):191-208 [4683037.001]
  • [Cites] Hum Pathol. 1996 Oct;27(10):1095-8 [8892598.001]
  • [Cites] Pathologe. 2003 Mar;24(2):128-35 [12673503.001]
  • [Cites] Am J Surg Pathol. 2001 Feb;25(2):219-28 [11176071.001]
  • [Cites] J Dermatol. 2001 Jul;28(7):383-7 [11510507.001]
  • [Cites] Am J Clin Pathol. 1994 Sep;102(3):331-40 [8085557.001]
  • [Cites] Am J Surg Pathol. 2001 Dec;25(12 ):1501-7 [11717539.001]
  • [Cites] Ultrastruct Pathol. 1993 Nov-Dec;17(6):611-22 [8122327.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Aug;137(1):33-42 [12377411.001]
  • [Cites] Am J Surg Pathol. 1998 Feb;22(2):141-7 [9500214.001]
  • [Cites] Verh Dtsch Ges Pathol. 1998;82:75-82 [10095420.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):459-69 [11905413.001]
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1228-38 [9777985.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):711-21 [15188137.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):393-4; author reply 394-6 [11981942.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):350-62 [8996162.001]
  • [Cites] Br J Cancer. 1997;75(1):79-86 [9000602.001]
  • [Cites] Cancer. 2004 Feb 25;102(1):41-54 [14968417.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13784-9 [11707590.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):489-96 [9130998.001]
  • [Cites] Am J Surg Pathol. 1979 Dec;3(6):535-42 [534390.001]
  • [Cites] Virchows Arch. 2004 Sep;445(3):215-23 [15173943.001]
  • (PMID = 16158184.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


8. Einenkel J, Ott R, Handzel R, Braumann UD, Horn LC: Characteristics and management of diaphragm involvement in patients with primary advanced-stage ovarian, fallopian tube, or peritoneal cancer. Int J Gynecol Cancer; 2009 Oct;19(7):1288-97
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics and management of diaphragm involvement in patients with primary advanced-stage ovarian, fallopian tube, or peritoneal cancer.
  • OBJECTIVES: The aim of this study was to determine the frequency of diaphragm involvement (DI) in cases of International Federation of Gynecology and Obstetrics (FIGO) stage IIIC and IV primary epithelial ovarian, fallopian tube, or peritoneal cancer; the frequency of use of different surgical techniques in managing diaphragm implants; and the procedure-associated morbidity.
  • METHODS: A retrospective analysis of consecutive patients undergoing primary surgery by a single surgical team between January 2005 and June 2007 was accomplished.
  • Patients with tumors of low malignant potential and nonepithelial histologic diagnosis and those who received neoadjuvant chemotherapy were excluded.
  • Diaphragm resection at the left hemidiaphragm and bilateral DRs are very rare in primary cases.
  • CONCLUSIONS: Surgical effort in achieving an optimum cytoreduction could be evaluated more precisely with parameters of DI and diaphragm-related treatment procedures.
  • [MeSH-major] Carcinoma / epidemiology. Diaphragm. Fallopian Tube Neoplasms / epidemiology. Muscle Neoplasms / epidemiology. Muscle Neoplasms / surgery. Ovarian Neoplasms / epidemiology. Peritoneal Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Comorbidity. Disease Progression. Female. Gynecologic Surgical Procedures / methods. Gynecologic Surgical Procedures / statistics & numerical data. Gynecologic Surgical Procedures / utilization. Humans. Middle Aged. Neoplasm Staging. Postoperative Complications / epidemiology. Prevalence. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Fallopian Tube Cancer.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19823067.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Mayerhofer K, Lozanov P, Bodner K, Bodner-Adler B, Mayerhofer-Gallenbacher N, Hudelist G, Czerwenka K: Immunohistochemical analysis of a primary ovarian leiomyosarcoma. Case report. Anticancer Res; 2003 Jul-Aug;23(4):3433-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical analysis of a primary ovarian leiomyosarcoma. Case report.
  • BACKGROUND: Primary ovarian leiomyosarcoma is an extremely rare malignant smooth muscle neoplasm.
  • We report a case of a primary leiomyosarcoma of the ovary managed at our institution.
  • CASE REPORT: Surgical exploration in a 71-year-old woman revealed a large left adnexal tumor and one separate metastatic implant in one part of the omentum, being classified as a primary ovarian leiomyosarcoma stage III C.
  • The patient was treated with an adjuvant chemotherapy regimen consisting of cisplatin and ifosfamide.
  • Immunohistochemically, the tumor showed a strong positive staining reaction for muscle actin, alpha-smooth muscle actin and neuron-specific enolase as well as a weak positive reaction for vimentin.

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12926085.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Endothelial Growth Factors; 0 / Intercellular Signaling Peptides and Proteins; 0 / Ki-67 Antigen; 0 / Lymphokines; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


10. Bodner K, Bodner-Adler B, Czerwenka K, Hudelist G, Kimberger O, Leodolter S, Mayerhofer K: Bcl-2 expression in a primary leiomyosarcoma of the ovary: a case report. Wien Klin Wochenschr; 2003 Mar 31;115(5-6):191-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl-2 expression in a primary leiomyosarcoma of the ovary: a case report.
  • BACKGROUND: Primary ovarian leiomyosarcoma is an extremely rare malignant smooth-muscle neoplasm with fewer than 30 documented cases worldwide.
  • Immunohistochemically, ovarian leiomyosarcomas are characterized by the expression of alpha-smooth muscle actin (alpha-SMA).
  • Until recently, no report investigated the role of bcl-2 expression in primary ovarian leiomyosarcoma.
  • We report the management and an immunohistochemical analysis of bcl-2 in a patient with primary leiomyosarcoma of the ovary.
  • Surgical exploration revealed a large left adnexal mass that had developed from the left ovary and infiltrated one part of the omentum adherent to the left adnexa.
  • Microscopically the left adnexal tumor consisted of spindle cells arranged in smooth-muscle bundles and fascicles.
  • Immunohistochemically, the tumor showed a strong staining reaction for muscle actin, alpha-SMA and neuron-specific enolase, and also a weak reaction for vimentin.
  • According to the FIGO staging system for ovarian cancer, the tumor was classified as a primary ovarian leiomyosarcoma stage III C, and the patient was treated with an adjuvant chemotherapy regimen consisting of cisplatin and ifosfamide.
  • Two days after the third cycle of cisplatin/ifosfamid she developed an apoplexy spontaneously and chemotherapy was therefore discontinued.
  • CONCLUSIONS: Beside the routine histological and immunohistochemical characteristics of primary ovarian leiomyosarcoma, strong staining for bcl-2 was detected.
  • In order to understand more about the nature and the behaviour of this highly malignant neoplasm and to be able to improve the treatment, the prognostic value of bcl-2 has to be investigated in additional studies.
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Fatal Outcome. Female. Humans. Ovariectomy. Ovary / pathology

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Postgrad Med. 1993 Jul-Sep;39(3):151-3 [8051647.001]
  • [Cites] Gynecol Oncol. 1987 Sep;28(1):116-20 [3308653.001]
  • [Cites] Br J Cancer. 1995 May;71(5):1003-7 [7734290.001]
  • [Cites] Exp Cell Res. 1991 Aug;195(2):277-83 [2070813.001]
  • [Cites] Gynecol Oncol. 1993 Mar;48(3):389-93 [8462904.001]
  • [Cites] Am J Pathol. 1996 Dec;149(6):1941-52 [8952529.001]
  • [Cites] N Engl J Med. 1993 Sep 2;329(10):690-4 [8393963.001]
  • [Cites] Arch Pathol Lab Med. 1991 Sep;115(9):941-5 [1929791.001]
  • [Cites] J Cell Biol. 1994 Jan;124(1-2):1-6 [8294493.001]
  • [Cites] Br J Cancer. 1999 Jul;80(10):1658-64 [10408415.001]
  • [Cites] Cell. 1991 Jun 28;65(7):1097-8 [1648446.001]
  • [Cites] Eur J Gynaecol Oncol. 1999;20(3):172-3 [10410877.001]
  • [Cites] Pathol Int. 2000 Feb;50(2):162-5 [10792777.001]
  • [Cites] J Obstet Gynaecol Res. 2000 Dec;26(6):401-7 [11152324.001]
  • [Cites] J Natl Cancer Inst. 1994 Apr 6;86(7):499-504 [8133533.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jan;82(1):293-9 [8989276.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Jul;83(14):5214-8 [3523487.001]
  • [Cites] Int J Gynecol Cancer. 2002 Nov-Dec;12(6):745-8 [12445253.001]
  • [Cites] Eur J Gynaecol Oncol. 1998;19(3):257-61 [9641226.001]
  • [Cites] Gynecol Oncol. 1997 Sep;66(3):519-25 [9299270.001]
  • [Cites] Gynecol Oncol. 1987 Feb;26(2):183-92 [3643159.001]
  • [Cites] Am J Obstet Gynecol. 1972 Jan 15;112(2):183-91 [4109398.001]
  • (PMID = 12741081.001).
  • [ISSN] 0043-5325
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


11. Werner JA, Dünne AA: Value of neck dissection in patients with squamous cell carcinoma of unknown primary. Onkologie; 2001 Feb;24(1):16-20
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of neck dissection in patients with squamous cell carcinoma of unknown primary.
  • Lymph node metastases of cancer of an unknown primary (CUP syndrome) are responsible for 3-5% of the malignant diseases in the head and neck area.
  • For a curative approach modified radical neck dissection combined with postoperative radiation therapy with or without chemotherapy should be considered in N1-N3 lymph node status.
  • A radical neck dissection with postoperative radiation therapy should only be approved in cases of infiltration of the internal jugular vein, the accessory nerve and/or the sternocleidomastoid muscle.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Head and Neck Neoplasms / secondary. Lymphatic Metastasis / pathology. Neck Dissection. Neoplasms, Unknown Primary / surgery
  • [MeSH-minor] Humans. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger GmbH, Freiburg
  • (PMID = 11441275.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 37
  •  go-up   go-down


12. Ludwig K: [Musculoskeletal lymphomas]. Radiologe; 2002 Dec;42(12):988-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary lymphomas of bone or skeletal muscle are rare entities.
  • The most frequent among these diseases are primary non-Hodgkin's lymphomas of bone.
  • They account for 3-5% of all bone tumors and 5% of all primary extranodal non-Hodgkin's lymphomas.
  • Primary manifestations of Hodgkin's disease in bone or skeletal muscle are rarities.
  • Primary non-Hodgkin's lymphomas of skeletal muscle are rarities as well.
  • Primary non-Hodgkin's lymphomas of bone can be found in any patient age.
  • Their differential diagnosis includes -- depending on the patient's age -- Ewing's sarcoma,malignant fibrous histiocytoma,metastases of small cell tumors and osteomyelitis.Further differential diagnoses are the peripheral primitive neuroectodermal tumor (PNET), osteosarcoma, eosinophilic granuloma and fibrosarcoma.
  • Treatment of primary non-Hodgkin's lymphomas uses combinations of chemotherapy and radiation therapy.
  • Operative treatment is reserved for the treatment of complications.
  • The prognosis of primary non-Hodgkin's lymphomas is reflected by 10-year-survival-rates without recurrence of more than 80% in unifocal manifestations.
  • [MeSH-major] Bone Neoplasms / diagnosis. Hodgkin Disease / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Magnetic Resonance Imaging. Muscle Neoplasms / diagnosis. Tomography, X-Ray Computed
  • [MeSH-minor] Bone and Bones / pathology. Humans. Muscle, Skeletal / pathology. Neoplasm Staging. Prognosis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12486552.001).
  • [ISSN] 0033-832X
  • [Journal-full-title] Der Radiologe
  • [ISO-abbreviation] Radiologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 0
  •  go-up   go-down


13. Eroğlu A, Kürkçüoğlu IC, Karaoğlanoğlu N, Alper F, Gündoğdu C: Extraskeletal Ewing sarcoma of the diaphragm presenting with hemothorax. Ann Thorac Surg; 2004 Aug;78(2):715-7
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ewing sarcoma is a relatively uncommon malignant bone neoplasm that usually occurs in children and young adults and involves the major long bones, pelvis, and ribs.
  • Primary diaphragmatic Ewing sarcoma is extremely rare.
  • To the best of our knowledge, only three cases of primary Ewing sarcoma of the diaphragm have been reported.
  • After drainage, a roentgenogram film, computed tomography, ultrasonography, and magnetic resonance image showed a giant mass on the right diaphragm.
  • Primary diaphragmatic tumor was resected totally by right posterolateral thoracotomy, and histologically, an extraskeletal Ewing sarcoma was identified.
  • The patient received adjuvant radio-chemotherapy, and there was no evidence of disease 10 months after the operation.
  • Although extremely rare, extraskeletal Ewing sarcoma should be kept in mind in the differential diagnosis of diaphragmatic soft tissue tumors.
  • [MeSH-major] Muscle Neoplasms / pathology. Sarcoma, Ewing / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Child. Combined Modality Therapy. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Dyspnea / etiology. Female. Hemothorax / etiology. Humans. Ifosfamide / administration & dosage. Mesna / administration & dosage. Neoplasm Invasiveness. Organ Specificity. Radiotherapy, Adjuvant. Remission Induction. Ribs / pathology

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15276562.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; NR7O1405Q9 / Mesna; UM20QQM95Y / Ifosfamide; MAID protocol
  •  go-up   go-down


14. Gupta P, Singh U, Singh SK, Kapoor R, Gupta V, Das A: Bilateral symmetrical metastasis to all extraocular muscles from distant rhabdomyosarcoma. Orbit; 2010 Jun;29(3):146-8
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After 2 weeks of initial surgery the patient developed bilateral axial proptosis and radiological imaging revealed bilateral extraocular muscle thickening involving all the extraocular muscles.
  • A biopsy of right superior rectus muscle confirmed rhabdomyosarcoma.
  • COMMENT: Although rhabdomyosarcoma is the commonest primary orbital malignant mass developing in young patients, it is an uncommon metastasis.
  • The present report describes one such patient with favorable initial response to chemotherapy and muscle thickness reverting to normal.
  • Metastasis from a distant site should be considered in differential diagnosis when evaluating a patient with bilateral enlargement of all extraocular muscles.
  • [MeSH-major] Muscle Neoplasms / secondary. Rhabdomyosarcoma / secondary. Scrotum / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease Progression. Follow-Up Studies. Humans. Male. Neoplasm Invasiveness / pathology. Neoplasm Staging. Oculomotor Muscles. Orbital Neoplasms / drug therapy. Orbital Neoplasms / secondary. Orchiectomy / methods. Risk Assessment

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20497080.001).
  • [ISSN] 1744-5108
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Kanamori M, Ohmori K, Nogami S, Maeda Y: Undifferentiated leiomyosarcoma showing various sarcomatous components with incidental B-cell lymphoma after tumor recurrence. J Orthop Sci; 2002;7(6):698-702
Genetic Alliance. consumer health - Leiomyosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • T2-weighted magnetic resonance images revealed a high signal intensity mass measuring 9 x 8 cm in the gluteus muscle.
  • The pathological diagnosis of repeated surgery was undifferentiated LMS that included various sarcomatous components, such as fibrosarcomatous, rhabdomyosarcomatous, and malignant fibrous histiocytoma-like elements.
  • A specimen from a supraclavicular lymph node showed the characteristics of malignant B-cell lymphoma (follicle type).
  • Adjuvant chemotherapy or radiation therapy was not performed because of the patient's advanced age.
  • The patient died from liver metastasis and dysfunction 5 years 8 months after the initial therapy.
  • This is a rare case of LMS with malignant lymphoma.
  • Considerable debate remains whether the B-cell lymphoma developed incidentally.
  • [MeSH-major] Leiomyosarcoma / pathology. Lymphoma, B-Cell / pathology. Muscle Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neoplasms, Second Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12486476.001).
  • [ISSN] 0949-2658
  • [Journal-full-title] Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
  • [ISO-abbreviation] J Orthop Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


16. Brecht IB, Treuner J: [Soft tissue sarcoma in children and adolescents: experiences of the cooperative Soft Tissue Sarcoma Group Studies (CWS-81 - 96)]. Handchir Mikrochir Plast Chir; 2004 Oct;36(5):275-81
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Soft tissue sarcoma in children and adolescents: experiences of the cooperative Soft Tissue Sarcoma Group Studies (CWS-81 - 96)].
  • The very heterogeneous group of paediatric soft tissue sarcomas account for approximately 7 % of all malignant childhood tumours.
  • The prognosis and biology of soft tissue sarcomas in children and adolescents vary greatly depending on histological subtype, the age of the patient, the primary site, the tumour size, tumour invasiveness and the extent of disease at diagnosis.
  • Since 1981, 2918 children and adolescents with soft tissue sarcomas were treated prospectively according to the common treatment protocols of the Cooperative Soft Tissue Sarcoma Study Group (CWS-81 - 96).
  • The multimodal treatment includes the use of surgery, chemotherapy and radiotherapy and should be planned by a multidisciplinary team.
  • [MeSH-major] Sarcoma / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Protocols. Child. Child, Preschool. Combined Modality Therapy. Connective Tissue / pathology. Female. Germany. Humans. Infant. Interdisciplinary Communication. Male. Muscle, Skeletal / pathology. Neoplasm Invasiveness / pathology. Neoplasm Staging. Patient Care Team. Prognosis. Prospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15503257.001).
  • [ISSN] 0722-1819
  • [Journal-full-title] Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft für Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft für Mikrochirurgie der Peripheren Nerven und Gefässe : Organ der Vereinigung der Deutschen Plastischen Chirurgen
  • [ISO-abbreviation] Handchir Mikrochir Plast Chir
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


17. Tanaka T, Toujima S, Utsunomiya T, Yukawa K, Umesaki N: Experimental characterization of recurrent ovarian immature teratoma cells after optimal surgery. Oncol Rep; 2008 Jul;20(1):13-23
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Minimal optimal surgery without chemotherapy is often performed for patients with ovarian immature teratoma, which frequently occurs in young women who hope for future pregnancies.
  • If tumors recur after the operation, anticancer drug chemotherapy is often administered, although few studies have highlighted differences between the recurrent and the primary tumor cells.
  • Therefore, we have established experimental animal models of recurrent ovarian immature teratoma cells after optimal surgery and characterized the anticancer drug sensitivity and antigenicity of the recurrent tumors.
  • Differential drug sensitivity and antigenicity of the tumor cells were compared between the primary and the nude mouse tumors.
  • Cultured primary cells showed a remarkably high sensitivity to paclitaxel, docetaxel, adriamycin and pirarubicin, compared to peritoneal cancer cells obtained from a patient with ovarian adenocarcinomatous peritonitis.
  • The drug sensitivity of teratoma cells to 5-fluorouracil, bleomycin or peplomycin was also significantly higher.
  • However, there was no significant difference in sensitivity to platinum drugs between the primary teratoma and the peritoneal adenocarcinoma cells.
  • As for nude mouse tumor cells, sensitivity to 12 anticancer drugs was significantly lower than that of the primary tumor cells, while there was little difference in sensitivity to carboplatin or peplomycin between the primary and nude mouse tumor cells.
  • Flow cytometry showed that the expression of smooth muscle actin (SMA) significantly decreased in nude mouse tumor cells when compared to cultured primary cells.
  • In conclusion, ovarian immature teratomas with normal karyotypes have a malignant potential to recur after minimal surgery.
  • During nude mouse transplantation, SMA-overexpressing cells appeared to be selectively excluded and nude mouse tumor cells were less sensitive to the majority of anticancer drugs than the primary tumor cells.
  • These results indicate that after optimal surgery for ovarian immature teratoma, recurrent cells can be more resistant to anticancer drugs than the primary tumors.
  • Therefore, it is likely that adjuvant chemotherapy lowers the risk of ovarian immature teratomas recurring after optimal surgery.
  • However, paclitaxel/carboplatin or docetaxel/carboplatin, which are the most effective chemotherapy treatments for epithelial ovarian cancer patients, are considered to be an alternative regimen, especially in the prevention of reproductive toxicity.
  • [MeSH-major] Neoplasm Recurrence, Local / pathology. Ovarian Neoplasms / pathology. Teratoma / pathology
  • [MeSH-minor] Adolescent. Animals. Cell Line, Tumor. Drug Screening Assays, Antitumor. Female. Flow Cytometry. Humans. Karyotyping. Mice

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18575713.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


18. Wei S, Carroll W, Lazenby A, Bell W, Lopez R, Said-Al-Naief N: Sinonasal teratocarcinosarcoma: report of a case with review of literature and treatment outcome. Ann Diagn Pathol; 2008 Dec;12(6):415-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sinonasal teratocarcinosarcoma: report of a case with review of literature and treatment outcome.
  • Sinonasal teratocarcinosarcoma is a highly malignant, polymorphous neoplasm that combines features of carcinosarcoma and teratoma.
  • Computerized tomography scans and magnetic resonance imaging revealed a large mass filling the left nasal cavity and extending to the cribriform plate with involvement of the ethmoid sinuses, lamina papyracea, and orbit.
  • The patient underwent a complex procedure for a T3N0 tumor.
  • The mesenchymal components consist of fibrous stroma and myxomatous areas, labeled with calponin and smooth muscle actin.
  • Immature neuroepithelium and olfactory neuroblastomalike tissue are highlighted with neuroendocrine markers.
  • Postoperatively, the patient had a rapid local recurrence of the tumor and underwent reexcision, and was treated with radiotherapy and chemotherapy.
  • Twelve months after his primary resection, computerized tomography scans revealed an intrathoracic tumor with dominant mass in the left hilum and metastases to the mediastinum, left pleural space, and both lungs.
  • Among 54 cases of reported sinonasal teratocarcinosarcoma, 67% of patients with initial single surgical resection and 80% of patients primarily treated with radiotherapy had recurrence, or metastatsis, or unresponsiveness to treatment.
  • Almost half of the patients died of tumor within 3 years of diagnosis, despite aggressive therapy.
  • Seventy percent of the patients who survived more than 1 year had the initial therapeutic regiments of combined surgery and adjuvant therapies, suggesting that aggressive therapeutic approaches may improve the treatment outcome.
  • [MeSH-major] Carcinosarcoma / diagnosis. Carcinosarcoma / therapy. Nose Neoplasms / diagnosis. Nose Neoplasms / therapy. Teratoma / diagnosis. Teratoma / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Magnetic Resonance Imaging. Male. Paranasal Sinuses / pathology. Paranasal Sinuses / surgery. Prognosis. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18995206.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


19. Le BH, Sandusky M: 81 year-old male with confusion and weakness. Brain Pathol; 2010 Jul;20(4):867-70
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma, the most common primary brain tumor, is a highly infiltrative, malignant astrocytic neoplasm that demonstrates a wide spectrum of morphologic heterogeneity.
  • Recently, data from the largest case series studying malignant gliomas with a PNET-like component suggest that the primitive component likely arises from the malignant glial component.
  • This report presents an example of glioblastoma with a prominent primitive neuroectodermal-like component in an 81 year-old male who, during the course of concurrent chemotherapy and radiation therapy, died five weeks following initial diagnosis.
  • [MeSH-major] Brain Neoplasms / pathology. Confusion / pathology. Glioblastoma / pathology. Muscle Weakness / pathology. Neuroectodermal Tumors, Primitive / pathology. Temporal Lobe / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20626749.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Switzerland
  •  go-up   go-down


20. de la Roza G, Naqvi A, Clark K: Gastrointestinal stromal tumors presenting as a prostatic mass. Can J Urol; 2009 Feb;16(1):4502-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These tumors are characterized by somatic mutations of c-KIT (CD117), a proto-oncogene that encodes a receptor tyrosine kinase normally expressed in the interstitial cell of Cajal that control the GI smooth muscle peristalsis, and an exquisite sensitivity to the action of the tyrokinase inhibitor imatinib mesylate (STI571; Gleevec).
  • We report two cases of gastrointestinal stromal tumor identified on prostatic biopsies, where a primary prostatic sarcoma was considered in the differential diagnosis.
  • In one of the cases, there was extensive local disease involving prostate, rectum, and pelvic wall, as well as metastatic disease that quickly lead to the patient's death despite aggressive treatment with imatinib mesylate and conventional chemotherapy.
  • In both cases, tissue samples from prostate and the rectum showed a malignant spindle cell neoplasm, which was positive for CD117 (c-kit).
  • Given their unique clinical management, gastrointestinal stromal tumors should be considered in the differential diagnosis of spindle cell lesions on prostatic needle biopsies and CD117 should be added to the immunohistochemical panel in the work-up of such lesions to avoid misinterpreting them as primary prostatic neoplasms.

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19222892.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


21. Huang WR, Li R, Jing Y, Zhang YZ, Wu XX, Gao CJ, Bo J, Yu L, Wang QS, Da WM: [Salvage therapy with proteasome inhibitor bortezomib for relapsed and refractory multiple myeloma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Dec;14(6):1146-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Salvage therapy with proteasome inhibitor bortezomib for relapsed and refractory multiple myeloma].
  • Multiple myeloma is a malignant disease with high incidence in middle-aged and old-aged population.
  • This observation is to study the clinical treatment effect of bortezomib in one relapsed multiple myeloma (MM) patient and one primary refractory MM patient.
  • And the disease became further aggressive with 4 courses of chemical therapy regimen including methylprednisolone, Arsenic trioxide, dexamethasone, cyclophosphamide, mitoxantrone, VM-26.
  • Therefore, the patient received therapy of bortezomib combined with doxrubicin, dexamethasone and thalidomide (VADT).
  • After one course of therapy with this VADT regimen, IgA in blood plasma decreased from 54 g/L to 6.6 g/L, and abnormal plasma cells in bone marrow decreased from 40% to 0.6%, and plasmacytoma on the patient's right upper chest wall almost absorbed.
  • But there was no obvious clinical effect after the second course of therapy of VADT, and the disease status became progressive again.
  • The second patient was MM patient with a light chain kappa type, III B stage.
  • There was no any effect after two courses of VAD therapy and one course of MOFP therapy.
  • The patient acquired near complete remission after one course of treatment with VADT.
  • And this patient got complete remission after three consecutive VADT therapy.
  • All the side effects could be tolerated and became disappeared after contraposing treatment and stopping the bortezomib regimen therapy.
  • The second patient complicated with severe subacute left hemiplegia after the bortezomib dose had been increased to 1.45 mg/m2 at the third time of the first VADT course and the complication became worst at the following day.
  • The upper limb muscle strength was only 1 grade and the lower limb muscle strength was 2 grade.
  • Then the condition improved with the support therapy and gradually recovered after two weeks.
  • Therefore, bortezomib is an effective target drug for therapy in refractory multiple myeloma, and more attentions to the side effects should be paid in order to deal with those side effects in time.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17204182.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Protease Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


22. Lopez-Beltrán A, Luque RJ, Vicioso L, Anglada F, Requena MJ, Quintero A, Montironi R: Lymphoepithelioma-like carcinoma of the urinary bladder: a clinicopathologic study of 13 cases. Virchows Arch; 2001 Jun;438(6):552-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lymphoepithelioma-like carcinoma (LELCA) of the urinary bladder is a rare variant of bladder cancer characterized by a malignant epithelial component densely infiltrated by lymphoid cells.
  • These neoplasms deserve recognition and attention, chiefly because they may be responsive to chemotherapy.
  • All tumors were muscle invasive.
  • [MeSH-minor] Aged. Aged, 80 and over. Aneuploidy. Carcinoma, Transitional Cell / chemistry. Carcinoma, Transitional Cell / mortality. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / surgery. DNA, Neoplasm / analysis. Female. Humans. Image Cytometry. Immunoenzyme Techniques. Keratins / analysis. Male. Middle Aged. Mucin-1 / analysis. Neoplasms, Multiple Primary / chemistry. Neoplasms, Multiple Primary / pathology. Survival Rate

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11469686.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Mucin-1; 68238-35-7 / Keratins
  •  go-up   go-down


23. Malpica A, Moran CA: Primitive neuroectodermal tumor of the cervix: a clinicopathologic and immunohistochemical study of two cases. Ann Diagn Pathol; 2002 Oct;6(5):281-7
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two cases of primary primitive neuroectodermal tumors of the cervix are presented.
  • Histologic sections showed the presence of a malignant neoplasm arranged in cords and with a vague nesting pattern.
  • Immunohistochemical studies revealed the neoplastic cells to be positive for antibodies for CD99 and focally for synaptophysin, while keratin, chromogranin, smooth muscle actin, desmin, and neurofilament protein were negative.
  • Both patients received adjuvant chemotherapy and remain alive 5 and 18 months after initial diagnosis, respectively.
  • The present cases highlight the importance of keeping primitive neuroectodermal tumors in the differential diagnosis of small cell neoplasms of the uterine cervix.
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Middle Aged

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002, Elsevier Science (USA)
  • (PMID = 12376920.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Siebenrock KA, Hertel R, Ganz R: Unexpected resection of soft-tissue sarcoma. More mutilating surgery, higher local recurrence rates, and obscure prognosis as consequences of improper surgery. Arch Orthop Trauma Surg; 2000;120(1-2):65-9
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unexpected resection of soft-tissue sarcoma. More mutilating surgery, higher local recurrence rates, and obscure prognosis as consequences of improper surgery.
  • Sixteen referred patients were reviewed after excision of an unexpected soft-tissue sarcoma of the extremities.
  • Eight tumors were located in the muscle deep to the fascia, and 8 lesions exceeded the size of 5 cm.
  • The lack of awareness by the primary physician towards the possibility of a malignant lesion was striking, although 11 of 16 tumors presented as a newly formed mass.
  • Four patients received adjuvant local radiation, with additional chemotherapy in 2 of them.
  • At an average follow-up of 4.5 years (range 15-149 months), 4 patients (25%) had developed distant metastases with a local recurrence in 3 (19%).
  • Evaluation by adequate imaging techniques, biopsy, and definitive resection and reconstruction should be performed by an oncologically trained orthopaedic surgeon.
  • Inadequate primary excision leads to a high local recurrence rate and more mutilating surgery and obscures the long-term prognosis.
  • [MeSH-major] Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Amputation. Chemotherapy, Adjuvant. Female. Forearm. Humans. Leg. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Radiotherapy, Adjuvant. Reoperation. Shoulder

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10653107.001).
  • [ISSN] 0936-8051
  • [Journal-full-title] Archives of orthopaedic and trauma surgery
  • [ISO-abbreviation] Arch Orthop Trauma Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] GERMANY
  •  go-up   go-down


25. De Flora S, Izzotti A, D'Agostini F, Balansky RM, Noonan D, Albini A: Multiple points of intervention in the prevention of cancer and other mutation-related diseases. Mutat Res; 2001 Sep 1;480-481:9-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multiple points of intervention are the target for dietary and pharmacological interventions aimed at preventing cancer and other diseases in which mutations in somatic cells play a pathogenetic role.
  • For instance, our studies showed that DNA adducts can be consistently detected in arterial smooth muscle cells from human atherosclerotic lesions.
  • Cancer chemoprevention has a dual goal, i.e. prevention of occurrence of the disease (primary prevention) and early detection and reversion of tumors at a premalignant stage (secondary prevention).
  • At a later stage, attempts can be made to prevent local recurrences as well as invasion and metastasis of malignant cells (tertiary prevention).
  • This classification is not intended to provide a rigid scheme, since several intervention points are reiterated several times over different phases of the process.
  • [MeSH-minor] Animals. Antioxidants / pharmacology. Biomarkers, Tumor. Diet. Disease Progression. Drug Therapy, Combination. Humans. Neoplasm Invasiveness / prevention & control. Neoplasm Metastasis / prevention & control. Retinoids / pharmacology. Risk Factors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11506795.001).
  • [ISSN] 0027-5107
  • [Journal-full-title] Mutation research
  • [ISO-abbreviation] Mutat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Biomarkers, Tumor; 0 / Retinoids
  • [Number-of-references] 59
  •  go-up   go-down


26. Kratz KG, Santillan A, Gu M, Bristow RE: Radical surgical cytoreduction of progressive leiomyomatosis peritonealis disseminata: a case report. J Reprod Med; 2009 Jul;54(7):447-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Leiomyomatosis peritonealis disseminata (LPD) is an uncommon, benign smooth muscle condition of the peritoneal cavity that appears clinically as a metastatic malignant neoplasm.
  • This unique case involves curative radical surgery after disease progression during depo-medroxyprogesterone acetate therapy.
  • Despite initial surgery and hormonal therapy, she had progression of disease.
  • Tumor response to megestrol acetate in vitro was evaluated and noted to be heterogeneous; therefore it was not given as adjuvant therapy.
  • Five years after radical surgery, she was without evidence of disease, CONCLUSION: Radical secondary cytoreductive surgery can achieve a durable remission for LPD refractory to primary surgical castration and depomedroxyprogesterone acetate therapy.
  • [MeSH-minor] Adult. Disease Progression. Dose-Response Relationship, Drug. Female. Humans. Medroxyprogesterone Acetate / administration & dosage. Peritoneal Cavity / cytology. Peritoneal Cavity / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19691262.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] C2QI4IOI2G / Medroxyprogesterone Acetate
  •  go-up   go-down


27. Waller CF: Imatinib mesylate. Recent Results Cancer Res; 2010;184:3-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They have a high selectivity against a specific molecular target known to be the cause for the establishment and maintenance of the malignant phenotype.
  • Imatinib has been shown to have remarkable clinical activity in patients with chronic myeloid leukemia (CML) and malignant gastrointestinal stroma tumors (GIST) leading to its approval for treatment of these diseases.Treatment with imatinib is generally well tolerated with a low incidence of severe side effects.
  • The most common adverse events (AE) include mild to moderate edema, muscle cramps, diarrhea, nausea, skin rashes, and myelosuppression.Several mechanisms of resistance have been identified.
  • Clonal evolution, amplification, or overexpression of Bcr-Abl as well as mutations in the catalytic domain, P-loop, and other mutations have been demonstrated to play a role in primary and secondary resistance to imatinib, respectively.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoplasms / drug therapy. Piperazines / therapeutic use. Protein Kinase Inhibitors / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Animals. Benzamides. Clinical Trials as Topic. Disease Progression. Drug Resistance, Neoplasm. Gastrointestinal Stromal Tumors / drug therapy. Humans. Imatinib Mesylate. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20072827.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  • [Number-of-references] 73
  •  go-up   go-down


28. Prunotto M, Bosco M, Daniele L, Macri' L, Bonello L, Schirosi L, Rossi G, Filosso P, Mussa B, Sapino A: Imatinib inhibits in vitro proliferation of cells derived from a pleural solitary fibrous tumor expressing platelet-derived growth factor receptor-beta. Lung Cancer; 2009 May;64(2):244-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined the in vitro effects of imatinib (Novartis Pharma AG, Basel, Switzerland) as a possible inhibitor of PDGFR pathway on cells derived from a recurrence of a pleural malignant solitary fibrous tumor (SFT).
  • Primary cell culture was characterised by immunofluorescence.
  • SFT-derived cells were treated with imatinib at different time points.
  • Western blotting for PDGFR-beta, phospho-PDGFR-beta or smooth muscle actin (SMA) was performed before and after 96 h of treatment with imatinib.
  • Western blotting showed that PDGFR-beta was highly expressed and phosphorylated in SFT-derived cells and imatinib treatment reduced PDGFR-beta phosphorylation and SMA expression.
  • With the limit of experimental findings, our results support a possible future application of imatinib as a candidate molecule in the target therapy of malignant SFTs over-expressing wild-type PDGFR.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cell Proliferation / drug effects. Piperazines / pharmacology. Pyrimidines / pharmacology. Receptor, Platelet-Derived Growth Factor beta / drug effects. Solitary Fibrous Tumor, Pleural / metabolism
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Benzamides. Blotting, Western. Cells, Cultured. Cisplatin / administration & dosage. Female. Fluorescent Antibody Technique. Fluorouracil / administration & dosage. Humans. Imatinib Mesylate. In Vitro Techniques. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Pneumonectomy. Radiotherapy. Receptor, Platelet-Derived Growth Factor alpha / biosynthesis

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19041155.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down






Advertisement